Evidence base — read this first
Part of a family of short synthetic peptides (2-4 amino acids) developed by Vladimir Khavinson's research group, each targeted at a specific tissue/organ. The evidence base for this entire peptide family shares the same limitation: it's concentrated almost entirely within this one research lineage (largely the same institute, often the same handful of authors), is mostly preclinical (rodent, cell-culture) or small Russian human pilot work, and hasn't been independently replicated by unaffiliated Western labs in a way this research pass could verify. None of these compounds is FDA or EMA approved for human use anywhere.
Benefits
Cardiogen (Ala-Glu-Asp-Arg) is pitched as a cardiac-tissue peptide within the same research program. No independently-verified specific study was confirmed for this compound in this research pass.
What's the actual idea behind this peptide?+
It's one of the Khavinson organ-specific bioregulators — a very short peptide targeting the gene-regulation machinery of heart and circulatory tissue specifically, on the theory that every organ produces its own regulatory peptides and supplementing them restores youthful function.
Is this well-established research or fringe?+
A large published body of work — decades, hundreds of papers — but concentrated almost entirely within the Khavinson group and Russian institutions, with limited independent replication. Not fringe, but not the same evidence weight as, say, Tesamorelin's FDA trials.
Looking for something specific, or placing a wholesale order? Send us a DM or email.